close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bayer Aktienges ADR (OP:BAYRY)

9.670 -0.100 (-1.02%)
Streaming Delayed Price Updated: 3:59 PM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 421,439
Open 9.720
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 9.770
Today's Range 9.620 - 9.730
52wk Range 4.790 - 10.03
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome
From Bayer
Via Business Wire
News headline image
RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints
From Bayer
Via Business Wire

Performance

YTD
+95.7%
+95.7%
1 Month
+26.7%
+26.7%
3 Month
+16.6%
+16.6%
6 Month
+28.4%
+28.4%
1 Year
+83.7%
+83.7%

More News

Read More
News headline image
Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia
From Bayer
Via Business Wire
Bayer Stock Fuels Hyper Bullish Retail Mood After Confirming New Stroke Study Met Key Goals Following 2023 Halt ↗
Via Stocktwits
News headline image
Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations
From Bayer
Via Business Wire
News headline image
Bayer’s Asundexian Met Primary Efficacy and Safety Endpoints in Landmark Phase III OCEANIC-STROKE Study in Secondary Stroke Prevention
From Bayer
Via Business Wire
News headline image
FDA Signs Off On Bayer's New Lung Cancer Drug — Early Results Look Promising ↗
Via Benzinga
News headline image
U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
From Bayer
Via Business Wire
News headline image
Siemens Warns Currency Headwinds Will Hit 2026 Results; CEO Defends Mid-Term Target ↗
Via Benzinga
News headline image
Daré Bioscience (DARE) Q3 2025 Earnings Transcript ↗
Via The Motley Fool
News headline image
Agricultural Conglomerate Bayer Confident In Long-Term Outlook Despite Litigation Risks ↗
Via Benzinga
News headline image
Bayer Launches “Science Delivers” Campaign Celebrating the Transformative Power of Science
From Bayer
Via Business Wire
News headline image
KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease
From Bayer
Via Business Wire
News headline image
Bayer’s Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause
From Bayer
Via Business Wire
News headline image
Top 3 Health Care Stocks You'll Regret Missing In October ↗
Via Benzinga
News headline image
Late-breaking data from Phase III OCEANIC-STROKE study accepted for presentation at World Stroke Congress 2025
From Bayer
Via Business Wire
News headline image
Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results ↗
Via Benzinga
News headline image
Bayer Partners with Cornfed Farms to Create First ForwardFarm in Midwest
From Bayer
Via Business Wire
News headline image
One A Day® Unveils Bold New Brand Identity and Platform: “The ONE for you”
From Bayer
Via Business Wire
News headline image
BlueRock Therapeutics reports positive 36-month results from Phase I trial of bemdaneprocel for treating Parkinson’s disease
From Bayer
Via Business Wire
News headline image
Bayer Selects Interpublic as Global Media, Production and Creative Agency Partner for Consumer Health Division
From Bayer
Via Business Wire
News headline image
Bayer to Highlight New Data for KERENDIA® (finerenone) at Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025
From Bayer
Via Business Wire
News headline image
Bayer First Company to Advance Cell Therapy as Well as Gene Therapy Against Parkinson’s Disease
From Bayer
Via Business Wire
News headline image
10 Years of Supporting Rural America: Bayer and Luke Bryan Team Up with Feeding America® to Tackle Hunger with “Take Care, Now” Campaign
From Bayer
Via Business Wire
News headline image
Agri-Science Giant Corteva Eyes Breakup To Shield Seed Unit From Future Risks: Report ↗
Via Benzinga

Frequently Asked Questions

Is Bayer Aktienges ADR publicly traded?
Yes, Bayer Aktienges ADR is publicly traded.
What exchange does Bayer Aktienges ADR trade on?
Bayer Aktienges ADR trades on the OTC Traded
What is the ticker symbol for Bayer Aktienges ADR?
The ticker symbol for Bayer Aktienges ADR is BAYRY on the OTC Traded
What is the current price of Bayer Aktienges ADR?
The current price of Bayer Aktienges ADR is 9.670
When was Bayer Aktienges ADR last traded?
The last trade of Bayer Aktienges ADR was at 12/05/25 03:59 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today